According to guidelines set by the National Comprehensive Cancer Network in 2022 and American Society of Clinical Oncology in 2021 [68, 69], neoadjuvant therapy is recommended for patients with HER2-positive BC with tumor size > 2 cm and/or a positive lymph node status (LN+). Here, ERBB2 is linked to neoplasm.